209 related articles for article (PubMed ID: 19075589)
1. Anticancer immunotherapy in combination with proapoptotic therapy.
Bruserud Ø; Ersvaer E; Olsnes A; Gjertsen BT
Curr Cancer Drug Targets; 2008 Dec; 8(8):666-75. PubMed ID: 19075589
[TBL] [Abstract][Full Text] [Related]
2. Combinatorial treatments including vaccines, chemotherapy and monoclonal antibodies for cancer therapy.
Baxevanis CN; Perez SA; Papamichail M
Cancer Immunol Immunother; 2009 Mar; 58(3):317-24. PubMed ID: 18704409
[TBL] [Abstract][Full Text] [Related]
3. [Chemotherapy and Anticancer Immune Responses].
Harada M
Gan To Kagaku Ryoho; 2016 May; 43(5):571-7. PubMed ID: 27210085
[TBL] [Abstract][Full Text] [Related]
4. The interplay of immunotherapy and chemotherapy: harnessing potential synergies.
Emens LA; Middleton G
Cancer Immunol Res; 2015 May; 3(5):436-43. PubMed ID: 25941355
[TBL] [Abstract][Full Text] [Related]
5. The need for improvement of the treatment of advanced and metastatic cervical cancer, the rationale for combined chemo-immunotherapy.
van Meir H; Kenter GG; Burggraaf J; Kroep JR; Welters MJ; Melief CJ; van der Burg SH; van Poelgeest MI
Anticancer Agents Med Chem; 2014 Feb; 14(2):190-203. PubMed ID: 24237223
[TBL] [Abstract][Full Text] [Related]
6. Combination of active specific immunotherapy or adoptive antibody or lymphocyte immunotherapy with chemotherapy in the treatment of cancer.
Zhang T; Herlyn D
Cancer Immunol Immunother; 2009 Apr; 58(4):475-92. PubMed ID: 18925393
[TBL] [Abstract][Full Text] [Related]
7. Combined chemoimmunotherapy of solid tumours: improving vaccines?
Nowak AK; Lake RA; Robinson BW
Adv Drug Deliv Rev; 2006 Oct; 58(8):975-90. PubMed ID: 17005292
[TBL] [Abstract][Full Text] [Related]
8. Rationale for the Combination of Dendritic Cell-Based Vaccination Approaches With Chemotherapy Agents.
Truxova I; Hensler M; Skapa P; Halaska MJ; Laco J; Ryska A; Spisek R; Fucikova J
Int Rev Cell Mol Biol; 2017; 330():115-156. PubMed ID: 28215530
[TBL] [Abstract][Full Text] [Related]
9. Does chemotherapy augment anti-tumor immunotherapy by preferential impairment of regulatory T cells?
Zhang L; Dermawan KT; Jin ML; Xiong SD; Chu YW
Med Hypotheses; 2008 Nov; 71(5):802-4. PubMed ID: 18691831
[TBL] [Abstract][Full Text] [Related]
10. Immunogenic chemotherapy: Dose and schedule dependence and combination with immunotherapy.
Wu J; Waxman DJ
Cancer Lett; 2018 Apr; 419():210-221. PubMed ID: 29414305
[TBL] [Abstract][Full Text] [Related]
11. Cancer-associated fibroblast-targeted strategy enhances antitumor immune responses in dendritic cell-based vaccine.
Ohshio Y; Teramoto K; Hanaoka J; Tezuka N; Itoh Y; Asai T; Daigo Y; Ogasawara K
Cancer Sci; 2015 Feb; 106(2):134-42. PubMed ID: 25483888
[TBL] [Abstract][Full Text] [Related]
12. The role of regulatory T lymphocytes in the induced immune response mediated by biological vaccines.
López M; Aguilera R; Pérez C; Mendoza-Naranjo A; Pereda C; Ramirez M; Ferrada C; Aguillón JC; Salazar-Onfray F
Immunobiology; 2006; 211(1-2):127-36. PubMed ID: 16446177
[TBL] [Abstract][Full Text] [Related]
13. Desirable cell death during anticancer chemotherapy.
Locher C; Conforti R; Aymeric L; Ma Y; Yamazaki T; Rusakiewicz S; Tesnière A; Ghiringhelli F; Apetoh L; Morel Y; Girard JP; Kroemer G; Zitvogel L
Ann N Y Acad Sci; 2010 Oct; 1209():99-108. PubMed ID: 20958322
[TBL] [Abstract][Full Text] [Related]
14. Combinational adenovirus-mediated gene therapy and dendritic cell vaccine in combating well-established tumors.
Xia D; Moyana T; Xiang J
Cell Res; 2006 Mar; 16(3):241-59. PubMed ID: 16541123
[TBL] [Abstract][Full Text] [Related]
15. Combination of DC Vaccine and Conventional Chemotherapeutics.
Dong W; Wei R; Shen H; Ni Y; Meng L; Du J
Anticancer Agents Med Chem; 2016; 16(5):558-67. PubMed ID: 26343140
[TBL] [Abstract][Full Text] [Related]
16. Combination strategies for enhancing the efficacy of immunotherapy in cancer patients.
Moschella F; Proietti E; Capone I; Belardelli F
Ann N Y Acad Sci; 2010 Apr; 1194():169-78. PubMed ID: 20536466
[TBL] [Abstract][Full Text] [Related]
17. Witch hunt against tumor cells enhanced by dendritic cells.
Locher C; Rusakiewicz S; Tesnière A; Ghiringhelli F; Apetoh L; Kroemer G; Zitvogel L
Ann N Y Acad Sci; 2009 Sep; 1174():51-60. PubMed ID: 19769736
[TBL] [Abstract][Full Text] [Related]
18. How immunotherapy can enhance the response to other modalities and improve outcome and quality of life.
Liu WM; Meyer B; Dalgleish AG
J BUON; 2009 Sep; 14 Suppl 1():S103-9. PubMed ID: 19785052
[TBL] [Abstract][Full Text] [Related]
19. Immunogenic anti-cancer chemotherapy as an emerging concept.
Haynes NM; van der Most RG; Lake RA; Smyth MJ
Curr Opin Immunol; 2008 Oct; 20(5):545-57. PubMed ID: 18573339
[TBL] [Abstract][Full Text] [Related]
20. Enhanced dendritic cell-based immunotherapy using low-dose cyclophosphamide and CD25-targeted antibody for transplanted Lewis lung carcinoma cells.
Son CH; Bae JH; Lee HR; Shin DY; Yang K; Park YS
J Immunother; 2015 Apr; 38(3):107-15. PubMed ID: 25751500
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
